Latest Headlines

Latest Headlines

Medtronic to buy cerebral aneurysm stealth startup Medina for $150M+

In its eighth disclosed acquisition this year, Medtronic will purchase vascular aneurysm player Medina Medical for $150 million plus additional undisclosed milestone payments. The stealthy startup already has a CE mark for its embolization device to treat cerebral aneurysm.

Can Baxalta hold off Shire with its own bid for Ariad?

Baxalta may not want to be snatched up at its young age, as it told Irish suitor Shire early this month. But that doesn't mean it doesn't want to land some deals itself--and Ariad Pharmaceuticals may be on its radar.

Amicus bags PhIII rare disease drug in $847M Scioderm buyout

Amicus Therapeutics has stepped in to snap up the late-stage rare disease biotech Scioderm, beefing up its orphan drug pipeline in exchange for $229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.

Abbott's next big acquisition: Wall Street wonders, if not St. Jude, then who?

Wall Street is taking Abbott's claim that it is not interested in St. Jude Medical at face value, paving the way for speculation about who the drug and devicemaker will buy instead as it seeks to deploy plentiful cash and bulk up in med tech following a wave of industry M&A.

Celgene nails down $7.2B takeover of Receptos

Celgene Thursday reported that it had completed its $7.2 billion buyout of Receptos. Celgene agreed to pay $232 per share for the San Diego-headquartered company, a nearly 18% premium.

Sweden's Meda weighs $1B sale of its U.S. business

Meda is no stranger to the M&A arena, last year inking a pact to buy Italy's Rottapharm. This time, though, it could wind up on the other side of the bargaining table.

On the heels of big production news, Novo Nordisk snaps up two diabetes drug developers

After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes and related metabolic problems.

Impatient Horizon accuses Depomed of stalling its shareholder meeting plans

Early this month, Horizon Pharma wrote to hostile target Depomed to get the ball rolling on requesting a special shareholders' meeting. And it's not happy about how that process has gone so far.

Greatbatch grabs Lake Regional Medical for $1.7B to expand surgical offerings

Greatbatch is snatching up Lake Region Medical for $1.73 billion to beef up its offerings and expand its global reach, months after the company announced it would spin off its neurostimulation unit to focus on building out its portfolio.